Medication-Assisted Treatment (MAT)
Medication-Assisted Treatment (MAT) is an evidence-based approach to treating substance use disorders that combines FDA-approved medications with counseling and behavioral therapies. MAT is considered the gold standard for opioid use disorder treatment and is also used for alcohol use disorder, reducing cravings, preventing relapse, and supporting long-term recovery.
FDA-Approved MAT Medications
Three primary medications are approved for opioid use disorder: buprenorphine (Suboxone, Sublocade), methadone, and naltrexone (Vivitrol). For alcohol use disorder, approved medications include naltrexone, acamprosate (Campral), and disulfiram (Antabuse). Each medication works through different mechanisms — buprenorphine is a partial opioid agonist that reduces cravings, methadone is a full agonist dispensed through certified programs, and naltrexone is an antagonist that blocks opioid effects.
How MAT Programs Operate
MAT programs integrate medication management with individual and group therapy sessions. Prescribers conduct initial assessments, order drug screenings, and monitor patients through regular follow-up visits. Treatment plans address both the physiological and psychological aspects of addiction, combining pharmacological support with cognitive behavioral therapy, motivational interviewing, and relapse prevention planning.
Prescribing Requirements
Since the elimination of the X-waiver requirement in January 2023 through the Consolidated Appropriations Act, any provider with a DEA license can prescribe buprenorphine for opioid use disorder. However, prescribers must still complete required training, and methadone can only be dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs). Electronic prescribing of controlled substances (EPCS) is increasingly required by state regulations.
MAT and 42 CFR Part 2
Substance use disorder treatment records, including MAT records, receive additional federal privacy protections under 42 CFR Part 2 beyond standard HIPAA requirements. These regulations restrict the disclosure of patient-identifying information from SUD treatment programs, requiring written patient consent for most disclosures. Behavioral health EHR systems must support segmented consent management to comply with both HIPAA and Part 2.
Billing for MAT Services
MAT services are billed using a combination of E/M codes for office visits, HCPCS codes for medication administration (such as J0570 for buprenorphine injection), and CPT codes for counseling services. Many states have expanded Medicaid coverage for MAT, and commercial payers increasingly cover these services. Prior authorization requirements vary by payer and medication.
FAQs
How long should a patient stay on MAT?
There is no universally recommended duration. SAMHSA guidelines suggest that patients on MAT for opioid use disorder should continue for a minimum of 12 months, and many patients benefit from long-term or indefinite maintenance.
Is MAT just replacing one drug with another?
No. MAT medications are carefully dosed to reduce cravings and withdrawal without producing euphoria. Research consistently shows that MAT reduces illicit opioid use, overdose deaths, and criminal activity while improving treatment retention.
What documentation is required for MAT programs?
MAT documentation must include initial assessments, drug screening results, medication consent forms, prescription monitoring program checks, treatment plans addressing both medication and counseling, and progress notes for each visit.
Can MAT be delivered via telehealth?
Yes. Federal and most state regulations now permit MAT prescribing via telehealth, including initial buprenorphine prescriptions, which was expanded during the COVID-19 public health emergency and made permanent through subsequent rulemaking.
Learn More
- Substance Abuse Billing Guide — MAT billing codes and documentation
- Best EHR for MAT Clinics — EHR systems with EPCS and PDMP integration
- Best EHR for Addiction Treatment — MAT management within addiction treatment EHRs